Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
52-week, open-label extension study of double-blind study ACP-103-069 to determine the
long-term safety and tolerability of pimavanserin for the treatment of irritability
associated with ASD in children and adolescents (aged 5 to 17 years).
ACP-103-069 is a 6-week, randomized, double-blind, fixed-dose, placebo controlled, parallel
group study of pimavanserin in children and adolescents with irritability associated with
autism spectrum disorder (ASD).